India’s Union Budget 2026-27 proposed five regional medical hubs and a five-year drive to make more medicines at home, The Economic Times reported. Presenting the budget, Finance Minister Nirmala Sitharaman told Parliament she would “launch a scheme to support states in establishing five regional medical hubs”. The centres, she said, are meant to draw more international patients to India. Each hub is envisaged as an integrated complex rather than a single hospital, combining medical services with education and research on one site.
The design is deliberate. Pairing treatment with training and research is meant to lift the quality of care offered to foreign patients, and to keep more of that work inside India. Medical tourism has become a recurring line in Indian budgets, and this year it sat beside measures on medicines, skills and traditional medicine rather than standing on its own. Sitharaman gave no per-hub cost and no construction timeline. The Economic Times reported the measure as a scheme to support states, not a network New Delhi would build itself. Whether the five hubs move from proposal to construction is the test that will matter, since a budget line commits money to an intention long before it commits it to a building.
Biopharma Shakti and the drug-supply plan
Alongside the hubs, the budget put money into domestic manufacturing. Sitharaman proposed the Biopharma Shakti, “with an outlay of Rs 10,000 crore over the next five years”, to build home production of biologics and biosimilars, The Economic Times reported. Biologics and biosimilars are among the costlier classes of medicine, and India still imports much of what it uses. Cutting that dependence, the government argued, would improve drug security and lower treatment costs. Both of those feed the price advantage that has long drawn foreign patients to Indian hospitals. The programme reaches into training as well, funding three new National Institutes of Pharmaceutical Education and Research and upgrades to seven existing institutes under the Biopharma Shakti banner, The Economic Times reported. For a destination that competes on price, cheaper and steadier domestic medicines are not a side issue, and they sit close to the centre of the case put to international patients.
What the budget does and does not settle
For the medical tourism trade, the budget reads as intent more than delivery. India already ranks among the larger destinations by projected value. Its market has been put on course to reach $16.2 billion by 2030, and separately to add several billion dollars of activity by 2026. State-level projects such as a planned health city in Telangana are already testing the integrated-hub model on the ground, a reminder that the idea is not new and that delivery has always been the harder part. What the budget adds is a national frame and a funding line, not a finished centre. The binding constraint on medical travel is capacity, not ambition, and none of the five hubs is capacity yet. Capacity is built hospital by hospital, and much of it will depend on which states take up the scheme and how fast. For a foreign patient, the parts that decide a trip, the visa, the coordination, the surgeon and the price, are settled well below the level of a budget speech.
Where a hub succeeds or stalls
A hospital building is the visible part of a medical hub, and the easiest part to fund. The harder parts are the ones a patient actually buys: a surgeon with a track record, a visa that clears in time, a coordinator who answers in the patient’s own language, and a price fixed before the flight. Those are set at the level of the hospital and the state, not the budget. India’s accredited private hospitals already do this well, and the risk in a national scheme is that the money builds the shell while the service lags behind. A hub that opens without the surgeons and the coordination is a building, not a destination. The budget can pay for the first. It cannot legislate the second.
What to watch
The near-term tests are specific. Watch which states take up the hub scheme, and on what timeline. Watch whether the Rs 10,000 crore Biopharma Shakti outlay is drawn down against its five-year schedule. Watch whether the three new pharmaceutical institutes reach a site and a start date. Until those move, the five regional medical hubs remain a proposal, and a later budget will have to fund them again.
